Latest Options News

Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.

Blackstone Minerals has completed its acquisition of IDM International, issuing over 692 million shares and 83 million options, significantly expanding its copper-gold portfolio with the Mankayan project in the Philippines.

State Street Global Advisors has announced a substantial cash distribution for the SPDR S&P/ASX 200 ESG ETF, reflecting the fund’s income and tax attributes for the year ending June 2025.

Oceania Healthcare has modernized its property portfolio and updated its dividend policy to align with a new strategic direction under CEO Suzanne Dvorak, aiming to meet New Zealand's growing aged care demand.

State Street Global Advisors has announced a 21.5897 cents per unit cash distribution for the SPDR S&P/ASX Small Ordinaries ETF for the period ending June 30, 2025, alongside franking and foreign tax credits.

Atomo Diagnostics has successfully closed a Share Purchase Plan and secured shareholder approval for a Tranche 2 Placement, raising a combined $1.53 million to support its ongoing operations.

Alvo Minerals has successfully closed its retail entitlement offer, raising $810,985 and bringing total proceeds from its recent capital raise to $1.56 million. The funds will support ongoing exploration at its Palma Cu/Zn Project and other mineral ventures in Brazil.

State Street Global Advisors announces a substantial cash distribution for the SPDR S&P World ex Australia Carbon Aware ETF, highlighting a blend of income and tax credits for investors.

State Street Global Advisors has announced the June 2025 distribution for the SPDR Dow Jones Global Real Estate ESG Tilted ETF, detailing income components and tax credits. Investors can expect a mix of cash and franking credits, with key dates for trading and reinvestment outlined.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

BWP Trust proposes to internalise its management by acquiring BWPM from Wesfarmers for $142.6 million, restructure 62 Bunnings leases to extend lease terms and options, and commit $86 million to capital upgrades. The transaction is forecast to be accretive to FY2026 distributions and requires investor approval.

BWP Trust and Wesfarmers have agreed on a transformative $142.6 million transaction involving management internalisation, lease extensions with Bunnings, and capital commitments to upgrade stores, aiming to boost income certainty and distribution growth.